心脏保护性乳腺放疗后的心脏风险:LAD剂量优于全心脏剂量
该横断面研究纳入2008至2018年加拿大三级中心接受3D适形或调强放疗的4908例乳腺癌患者(2223例左侧),中位随访10.8年。左侧患者中最大LAD剂量对心脏事件的区分度优于平均心脏剂量,最大LAD≥12 Gy EQD2独立关联更高心脏风险,而平均心脏剂量≥2 Gy无关联。
要点
- 左侧乳腺癌放疗后最大LAD剂量≥12 Gy EQD2独立关联心脏事件风险升高。
- 最大LAD剂量对心脏风险的区分度优于平均心脏剂量。
- 支持基于LAD的放疗计划与呼吸运动管理以降低远期心血管风险。
核心结论
- 在心脏保护性乳腺放疗中,LAD剂量与心脏事件相关,而全心脏剂量指标未显示关联。
研究设计与样本
- 横断面研究,纳入2008至2018年加拿大三级中心接受3D适形或调强放疗的乳腺癌患者,主要分析左侧乳腺癌患者。
- 共纳入4908例乳腺癌患者,其中2223例为左侧乳腺癌。
- 中位随访10.8年(IQR 8.4-13.1)。
主要发现
- 10年心脏事件或CAD累积发生率为5.0%(95%CI 4.1-6.0)。
- 左侧乳腺癌患者中,最大LAD剂量的C指数为0.58(95%CI 0.52-0.64),优于平均心脏剂量的0.53(95%CI 0.47-0.60)。
- 多变量分析中,最大LAD≥12 Gy与更高心脏风险独立相关(sHR=1.81;95%CI 1.04-3.16;P=.04)。
- 平均心脏剂量≥2 Gy与心脏风险无关联(P=.99)。
关键数值与推荐
- 数据驱动切点分析确定最大LAD剂量12 Gy EQD2为最佳风险分层阈值。
- 12 Gy EQD2对应42.5 Gy/16次方案的物理剂量约10.5 Gy,对应26 Gy/5次方案的物理剂量约7 Gy。
- 心脏事件定义为心肌梗死或因不稳定心绞痛(急性冠脉综合征)、心律失常、心力衰竭、心包炎或心肌炎就诊或住院。
临床怎么用
- 左侧乳腺癌放疗计划应关注LAD剂量而非仅全心脏剂量,尽量将最大LAD剂量控制在12 Gy EQD2以下。
- 可结合呼吸运动管理以进一步降低LAD受量。
局限性
- 为单中心横断面研究,结果需外部验证。
- 心脏事件评估依赖纵向随访数据,可能存在漏诊或分类偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Radiotherapy for breast cancer exposes the heart to incidental radiation, and historical data have shown a dose-dependent increase in associated cardiac events. Although whole-heart dose metrics are commonly used for risk assessment, emerging evidence suggests that dose to the left anterior descending coronary artery (LAD) may better capture risk. OBJECTIVE: To compare the ability of heart and LAD radiation dose metrics to predict cardiac risk after breast radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study of patients with breast cancer who were treated with either 3-dimensional conformal or intensity-modulated radiotherapy from 2008 to 2018 at a tertiary care center in Canada. The primary analysis included patients with left-sided breast cancer. Cardiac events were assessed using longitudinal follow-up data. Dosimetry was derived from computed tomography plans using automated segmentation and converted to equivalent dose in 2-Gy fractions (EQD2). Data were analyzed from September 2024 to April 2026. MAIN OUTCOMES AND MEASURES: Adverse cardiac events defined as myocardial infarction or hospital admission or emergency department visit for unstable angina (ie, acute coronary syndrome), arrhythmia, heart failure, pericarditis, or myocarditis. The incidence of coronary angiography and coronary revascularization was also captured as coronary artery disease (CAD). Discrimination for dose metrics was performed with receiver operator characteristic curves and competing-risks regression (Fine and Gray), adjusted for cardiovascular risk factors. RESULTS: The analysis included 4908 patients with breast cancer of whom 2223 had left-sided breast cancer. During a median (IQR) follow-up period of 10.8 (8.4-13.1) years, cumulative incidence of cardiac event or CAD was 5.0 (95% CI, 4.1-6.0) at 10 years. A data-driven cut point analysis identified 12 Gy EQD2 as the maximum LAD dose that best stratified risk. Among patients with left-sided breast cancer, maximum LAD dose (concordance [C] index, 0.58; 95% CI, 0.52-0.64) discriminated better than mean heart dose (C index, 0.53; 95% CI, 0.47-0.60). In multivariable analysis, maximum LAD of 12 Gy or greater was independently associated with higher cardiac risk (subdistribution hazard ratio = 1.81; 95% CI, 1.04-3.16; P = .04), whereas mean heart dose of 2 Gy or greater was not associated (P = .99). For clinical context, the 12-Gy EQD2 for maximum LAD dose corresponds to a physical dose of approximately 10.5 Gy for 42.5 Gy in 16 fractions and 7 Gy for 26 Gy in 5 fractions. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of heart-sparing breast radiotherapy, LAD dose was associated with cardiac events, whereas whole-heart metrics was not. These findings support LAD-based planning and respiratory motion management to reduce long-term cardiovascular risk in patients with breast cancer undergoing radiotherapy.
引用
- Quirk S, Atkins KM, Logie N, et al. Cardiac Risk After Heart-Sparing Breast Radiotherapy. JAMA Oncol. 2026. PMID: 42390858. doi:10.1001/jamaoncol.2026.2066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。